As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat
This article was originally published in PharmAsia News
Executive SummaryBEIJING - As Charles River Laboratories and WuXi PharmaTech count down toward crucial shareholder votes on Aug. 5 - on whether their proposed union should go forward or be shot down - the American and Chinese drug research outfits have issued a new call for ratification of the plan
You may also be interested in...
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).